Nirsevimab regulatory submission accepted by FDA for the prevention of RSV lower respiratory tract disease in infants and children up to age 24 months .- AstraZeneca + Sanofi
AstraZeneca’s Biologics License Application (BLA) for nirsevimab has been accepted for review by the FDA for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and infants entering or during their first RSV season, and for children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.
Nirsevimab is being developed and commercialised by AstraZeneca in collaboration with Sanofi and is the first single-dose preventative option for the broad infant population, including those born healthy, at term or preterm, or with specific health conditions.
The FDA has indicated it will work to expedite its review. The Prescription Drug User Fee Act date, the FDA target action date for its decision, is in the third quarter of 2023. If approved at that time, nirsevimab will be available in the US for the 2023/2024 RSV season.
RSV is a very contagious virus that can lead to serious respiratory illness, according to the Centers for Disease Control and Prevention. In the US, RSV is the leading cause of hospitalisation for babies under one. Any infant can be hospitalised in their first RSV season and about 75% of infants hospitalised for RSV in the US were born at term with no underlying conditions.
The BLA was based on results from the comprehensive nirsevimab clinical development programme, including the MELODY Phase III (primary cohort and all subjects), MEDLEY Phase II/III (first and second RSV season), and Phase IIb trials. Data from the MELODY trial was published in the New England Journal of Medicine in March 2022 ( previously cited) and demonstrated a reduction in the incidence of medically-attended lower respiratory tract infections (LRTI) caused by RSV by 74.5% (95% CI 49.6, 87.1; p<0.001) vs. placebo through day 151 (a typical rsv season) with a single dose. nirsevimab also demonstrated a comparable safety and tolerability profile to synagis (palivizumab) in the medley phase ii iii trial, with occurrence of treatment emergent adverse events (teaes) or treatment emergent serious adverse events (tesaes) similar between groups.></0.001)>
In November 2022, nirsevimab was granted marketing authorisation in the European Union for the prevention of RSV lower respiratory tract disease in newborns and infants during their first RSV season, under the name Beyfortus. Additional global regulatory submissions are underway.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.